Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and a reduced ejection fraction with or without type 2 diabetes. The risk of worsening heart failure or cardiovascular death...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 381; no. 21; pp. 1995 - 2008
Main Authors: McMurray, John J.V, Solomon, Scott D, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, Sabatine, Marc S, Anand, Inder S, Bělohlávek, Jan, Böhm, Michael, Chiang, Chern-En, Chopra, Vijay K, de Boer, Rudolf A, Desai, Akshay S, Diez, Mirta, Drozdz, Jaroslaw, Dukát, Andrej, Ge, Junbo, Howlett, Jonathan G, Katova, Tzvetana, Kitakaze, Masafumi, Ljungman, Charlotta E.A, Merkely, Béla, Nicolau, Jose C, O’Meara, Eileen, Petrie, Mark C, Vinh, Pham N, Schou, Morten, Tereshchenko, Sergey, Verma, Subodh, Held, Claes, DeMets, David L, Docherty, Kieran F, Jhund, Pardeep S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna-Maria
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 21.11.2019
Subjects:
Aged
Antidiabetics
Benzhydryl Compounds - adverse effects
Benzhydryl Compounds - therapeutic use
Cardiology and Cardiovascular Disease
Cardiovascular Agents - therapeutic use
Cardiovascular Diseases - mortality
Clinical outcomes
Clinical trials
Combined Modality Therapy
Congestive heart failure
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - complications
Diabetes Mellitus, Type 2 - drug therapy
Drug dosages
Drug therapy
Drug Therapy, Combination
Ejection fraction
Evidence-based medicine
Female
Glucosides - adverse effects
Glucosides - therapeutic use
Glycated Hemoglobin A - analysis
Heart failure
Heart Failure - complications
Heart Failure - drug therapy
Hemoglobin
Hospitalization
Humans
Hypoglycemia
Intravenous administration
Kaplan-Meier Estimate
Kardiologi och kardiovaskulära sjukdomar
Male
Middle Aged
Patient safety
Renal function
Sodium
Sodium-glucose cotransporter
Sodium-Glucose Transporter 2 Inhibitors - adverse effects
Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Stroke Volume - drug effects
Ventricular Dysfunction, Left - complications
Ventricular Dysfunction, Left - drug therapy
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this randomized, placebo-controlled trial, investigators evaluated the effects of the sodium–glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and a reduced ejection fraction with or without type 2 diabetes. The risk of worsening heart failure or cardiovascular death was lower among those who received dapagliflozin, regardless of the presence or absence of diabetes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1911303